Porcilis PCV M Hyo ID pack shots
Launch Of New Vaccine For Pigs In Great Britain
2 weeks ago 
193 views
MSD Animal Health launches new vaccine in Great Britain that will make it easier to protect piglets from four major diseases in just one intradermal vaccination event
MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), has launched its latest pig vaccine in Great Britain, PORCILIS® PCV M Hyo ID. The ready-to-use intradermal vaccine offers protection against two of the most common pig pathogens, Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae(M. hyo), and represents an important step forward for practical pig vaccination.
PORCILIS® PCV M Hyo ID offers vaccination programme flexibility for producers as it is is compatible for mixing with PORCILIS® LAWSONIA ID. It can also be co-administered on the same day (not mixed) with PORCILIS® PRRS meaning piglets can be protected against four key diseases within a single adminstration using the IDAL Twin device. Not only does this make protecting pigs from endemic challenges simpler for farmers and vets, but administration through the IDAL® device also offers key animal welfare benefits, including less pain and stress for pigs, reduced risk for iatrogenic transmission of pathogens between pigs, reduced tissue damage and no risk of broken needles.
The innovative vaccine, was formulated by combining M. hyo, and PCV2 in a single low volume dose (0.2 ml), and can be administered to pigs from three weeks of age, including pregnant and lactating sows.
“Pig producers are operating within an intense and fast-moving environment thanks to tighter margins, workforce shortages and rising welfare expectations so they need animal health solutions that are practical and effcacious. We are therefore excited to be expanding our trusted PORCILIS® ID range to further support producers and their vets,” said Dr Serena Shanahan, MRCVS, Veterinary Technical Manager at MSD Animal Health. “PORCILIS® PCV M Hyo ID makes it easier than ever for pig producers to protect their animals against four major diseases with just one, simple, needle-free intervention. This enables vets and producers to streamline protocols saving time and effort whilst maintaining efficacy.”
The diseases caused by PCV2 and M. hyo are associated with increased morbidity and mortality in piglet populations. Concurrent infection of PCV2 and M. hyo can cause severe respiratory disease and lung lesions as well as weight loss during the finishing period. PORCILIS® PCV M Hyo ID allows farmers to vaccinate piglets against both infectious agents at once, while also providing efficiency, convenience and flexibility. Intradermal vaccines also provide sustainability benefits due to less packaging, waste and transport and lower cold chain volume requirements.
“This innovative vaccine is an important step forward for practical piglet vaccination, strengthens our intradermal range and demonstrates MSD Animal Health’s commitment to pioneering science and technology solutions that are shaping the future of animal health,” added Dr Shanahan.
With Veterinary Medicines Directorate approval received in October 2025, PORCILIS® PCV M Hyo ID is now the fifth pig vaccine in Great Britain from MSD Animal Health that is administered through intradermal, needle-free application with IDAL® technology.
For more information about MSD Animal Health’s pig product portfolio, visit https://www.msd-animal-health.com/products/swine/.
More from MSD Animal Health
- Veterinary Medicines Directorate Approves NUMELVI® (atinvicitinib) Tablets for Dogs
- Calf Vaccines Identified as Low-hanging Fruit in Antibiotic Reduction
- Study Uncovers Hidden Colostrum Failures Behind Costly Calf Scours
- AHDB data highlights opportunity to strengthen abortion control in UK flocks
- Rising Lungworm and Resistance Fears Prompt Vaccination Advice Pre-Turnout
1 week ago